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INTRODUCTION
The second most common cancer in Korean women is 
breast cancer, and there were 19,219 newly diagnosed breast 
cancer cases in Korea in 2015. Although there have been ad-
vancements in the understanding of the disease and its treat-
ments, the incidence and mortality of breast cancer has in-
creased constantly throughout the past 15 years in Korea [1].
Adjuvant radiotherapy (RT) is a well-established compo-
nent of standard care for the management of patients with in-
vasive breast cancer and ductal carcinoma in situ (DCIS) of 
the breast [2,3]. RT for breast cancer has changed dramatically 
in the recent two decades after multiple randomized trials. 
These trials have not only established new standards of care 
but have also raised additional questions about appropriate 
management [4]. Surveys on patterns of practice show varia-
tions in clinical practice amongst practitioners, and these re-
sults can assist in creating guidelines and identifying areas of 
controversy that drive future clinical trials [5]. Research 
groups from the United States, European countries, Australia, 
and China have reported a large degree of variation in prac-
tice patterns and there is controversy regarding the appropri-
ate dose-fractionation schedule, application of regional nodal 
irradiation (RNI) and its coverage, and RT omission in pa-
tients at low risk of recurrence [4-9]. The first Korean study 
on patterns of care for breast cancer was published in 2007, 
but its interest was limited to the evaluation and treatment in 
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Adjuvant radiotherapy (RT) is a well-established treatment for 
breast cancer. However, there is a large degree of variation and 
controversy in practice patterns. A nationwide survey on the pat-
terns of practice in breast RT was designed by the Division for 
Breast Cancer of the Korean Radiation Oncology Group. All 
board-certified members of the Korean Society for Radiation 
Oncology were sent a questionnaire comprising 39 questions on 
six domains: hypofractionated whole breast RT, accelerated par-
tial breast RT, postmastectomy RT (PMRT), regional nodal RT, 
RT for ductal carcinoma in situ, and RT toxicity. Sixty-four radia-
tion oncologists from 54 of 86 (62.8%) hospitals responded. 
Twenty-three respondents (35.9%) used hypofractionated whole 
breast RT, and the most common schedule was 43.2 Gy in 16 
fractions. Only three (4.7%) used accelerated partial breast RT. 
Five (7.8%) used hypofractionated PMRT, and 40 (62.5%) had 
never used boost RT after chest wall irradiation. Indications for 
regional nodal RT varied; ≥pN2 (n=7) versus ≥pN1 (n=17) ver-
sus ≥pN1 with pathologic risk factors (n=40). Selection criteria 
for internal mammary lymph node (IMN) irradiation also varied; 
only four (6.3%) always treated IMN when regional nodal RT was 
administered and 30 (46.9%) treated IMN only if IMN involve-
ment was identified through imaging. Thirty-one (48.4%) consid-
ered omission of whole breast RT after breast-conserving sur-
gery for ductal carcinoma in situ based on clinical and pathologic 
risk factors. Fifty-two (81.3%) used heart-sparing techniques. 
Overall, there were wide variations in the patterns of practice in 
breast RT in Korea. Standard guidelines are needed, especially 
for regional nodal RT and omission of RT for ductal carcinoma in 
situ.
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patients treated with mastectomy and postmastectomy RT 
(PMRT) [10]. No Korean group has conducted surveys on 
patterns of practice so far, although breast cancer is one of the 
most common diseases treated with RT [11].
The purpose of this study was therefore to report the pat-
terns of national practice in RT for breast cancer in Korea, and 
to support the need for new evidence-based guidelines and 
future research.
METHODS
A nationwide survey on the patterns of practice in RT for 
breast cancer was designed by the Division for Breast Cancer 
of the Korean Radiation Oncology Group (KROG). The 
questionnaire-based survey comprised 39 questions on six 
domains: (1) hypofractionated whole breast RT (WBRT), (2) 
accelerated partial breast RT, (3) PMRT, (4) RNI, (5) RT for 
DCIS, and (6) RT toxicity. The questionnaire was piloted 
amongst the members of the Division for Breast Cancer of 
KROG, and minor modifications were made before starting 
the study. This study was conducted under the authorization 
and cooperation of the KROG.
All board-certified members of the Korean Society for Ra-
diation Oncology were invited to participate in the study via 
e-mail in June 2017, and participation was voluntary. Study 
data collected was analyzed for each question to evaluate vari-
ations of practice in RT.
RESULTS
Sixty-four radiation oncologists from 54 out of 86 (62.8%) 
hospitals responded in June 2017. Of the respondents, 53 
(82.8%) worked for academic-affiliated hospitals and 37 
(57.8%) worked for hospitals with more than two radiation 
oncologists, which qualifies a hospital as a radiation oncology 
training center. The respondents were divided based on the 
number of breast cancer patients they treated per month, with 
nine (14.1%) treating more than 30 breast cancer patients, 13 
(20.3%) treating 21 to 30, 23 (35.9%) treating 11 to 20, and 19 
(29.7%) treating fewer than 10. The respondents were also di-
vided based on the number of years they had been practicing 
as radiation oncologists, with 24 (37.5%) practicing for more 
than 15 years, 11 (17.2%) practicing for 10 to 14, 14 (21.9%) 
practicing for 5 to 9, and 15 (23.4%) practicing for less than 5.
Hypofractionated whole breast radiotherapy for invasive 
breast cancer
Twenty-three radiation oncologists (35.9%) stated that they 
used hypofractionated WBRT in the management of early-
stage breast cancer. Among the respondents who used hypo-
fractionation, 12 (52.2%) stated that the use of hypofraction-
ation was at the physician’s discretion, and 11 (47.8%) stated 
that it was decided through a shared decision-making process. 
Seventeen respondents applied hypofractionation in WBRT 
only, and six applied it in both WBRT and RNI. Respondents 
stated that a younger age, left-sided breast cancers, triple-neg-
ative breast cancers, a history of chemotherapy, and other ad-
verse pathologic features were contraindications for hypofrac-
tionation.
Most radiation oncologists applied more than 40 Gy mainly 
in 16 fractions, and used boost RT as well. The most common 
hypofractionation schedule prescribed was 43.2 Gy in 16 frac-
tions, followed by 42.4 Gy in 16 fractions and 39 Gy in 13 
fractions. Regarding RT technique, field-in-field technique 
(91.3%) was the most preferred, and intensity-modulated RT 
(39.1%) or three dimensional-conformal RT (39.1%) was of-
ten applied as well (Table 1).
The reasons that 41 of the surveyed radiation oncologists 
did not use hypofractionation were as follows: they thought 
that it was not necessarily required in Korea, because of easy 
access to medical facilities, low medical costs for cancer pa-
tients, and widespread additional private insurance (43.8%); 
they were concerned about reimbursement, because the Korean 
healthcare service payment is on a fee-for-service basis (35.9%); 
and, they felt that the long-term data of hypofractionated 
WBRT was still insufficient (34.4%).
Accelerated partial breast radiotherapy 
Only three radiation oncologists (4.7%) used accelerated 
partial breast RT. They all applied intensity-modulated RT, 
and one of them applied CyberKnife® (Accuray Inc., Sunnyvale, 
USA) as well. Different guidelines were followed for accelerat-
ed partial breast RT; one responder followed the American 
Society for Radiation Oncology (ASTRO) guidelines, one fol-
lowed the ASTRO and Groupe Européen de Curiethérapie‐
European Society for Radiation Oncology guidelines, and one 
followed institutional policy.
Postmastectomy radiotherapy 
Five radiation oncologists (7.8%) used hypofractionated 
PMRT. Fractionation schedules were 43.2 Gy in 16 fractions 
(n = 2), 45.9 Gy in 17 fractions (n = 2), and 40.05 Gy in 15 
fractions (n= 1).
Forty respondents (62.5%) had never used boost RT, but 
eight (12.5%) always used boost RT after chest wall irradia-
tion. Sixteen respondents (25.0%) used boost RT selectively 
for close resection margins (n= 14), pT4 (n= 7), pT3 (n= 2), 
and the presence of lympho-vascular space invasion (n= 2). 
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Forty respondents (62.5%) used bolus on either the entire 
chest wall or scar only. Twenty-eight (43.8%) and 46 (71.9%) 
did not use boost RT and bolus after breast reconstruction, 
respectively.
For RT techniques, standard or partial wide tangents were 
the most preferred (82.8%). Intensity-modulated RT, reverse 
hockey stick technique, and mixed photon and electron tech-
nique were applied as well (Table 2).
Regional nodal irradiation
Seven radiation oncologists (10.9%) applied RNI only for 
patients with 4 or more axillary lymph nodes (LNs) involve-
ment. Seventeen (26.6%) always applied RNI for patients with 
1–3 axillary LNs involvement. However, the majority of the 
respondents (62.4%) additionally considered pathologic risk 
factors, such as LN-related parameters (number, axillar level, 
nodal ratio, and extracapsular extension), lympho-vascular 
space invasion, molecular subtype, and tumor size, along with 
axillary LN involvement.
The questionnaire provided a clinical case scenario of an 
early-stage breast cancer patient with 1–2 positive sentinel LN 
undergoing breast-conserving surgery (BCS) without further 
axillary dissection, simulating the American College of Sur-
geons Oncology Group (ACOSOG) Z0011 trial. Eight re-
spondents (12.5%) used standard tangents, and 32 (50.0%) 
used high tangents with or without supraclavicular LN (SCN) 
irradiation. Twenty (31.3%) included SCN and only two 
(3.1%) included internal mammary LN (IMN) in the RT field.
With regard to IMN irradiation when applying RNI, only 
Table 1. Hypofractionated whole breast RT
Survey responses
Respondents 
No. (%)
Use of hypofrac-
tionation
Yes 23 (35.9)
No 41 (64.1)
Choice of hypo-
fractionation*
Shared decision 11 (47.8) 
Physician’s discretion 12 (52.2) 
Indication* Per ASTRO guideline, WBRT only 9 (39.1) 
Per institutional policy, WBRT only 8 (34.8) 
Per institutional policy, WBRT and RNI 6 (26.1) 
Contraindications 
(duplicated)*
None (all hypofractionation) 4 (17.4) 
Left-sided breast cancers 2 (8.7) 
Young age 5 (21.7) 
Triple-negative breast cancers 3 (13.0) 
Chemotherapy 4 (17.4) 
Others 2 (8.7) 
Fractionation 
schedules, 
WBRT*
2.5 Gy×16 fractions 2 (8.7)†
2.6 Gy×16 fractions 1 (4.3)
2.65 Gy×16 fractions 4 (17.4)
2.65625 Gy×16 fractions 2 (8.7)
2.66 Gy×16 fractions 2 (8.7)
2.67 Gy×15 fractions 2 (8.7)
2.67 Gy×16 fractions 1 (4.3)
2.7 Gy×16 fractions 6 (26.1) 
3 Gy×13 fractions 4 (17.4)†
Boost RT* Yes 22 (95.7)†
No 2 (8.7)†
Fractionation 
schedules, 
boost*
3.5 Gy 1 (4.3) 
3.2 Gy (simultaneous integrated boost) 1 (4.3) 
3.15 Gy (simultaneous integrated boost) 1 (4.3) 
3 Gy 10 (43.5)†
2.7 Gy 2 (8.7)
2.67 Gy 1 (4.3) 
2.65 Gy 1 (4.3) 
2.5 Gy 3 (13.0)
2 Gy 2 (8.7)
Employed  
techniques  
(duplicated)*
Field-in-field technique 21 (91.3)
Intensity-modulated RT 9 (39.1)
3D-conformal RT with wedge 9 (39.1)
RT =radiotherapy; ASTRO =American Society for Radiation Oncology; 
WBRT=whole breast radiotherapy; RNI= regional nodal irradiation; 3D=three 
dimensional.
*Percentage of respondents who responded “Yes” to use of hypofraction-
ation; †A respondent used different fractionation schedules; 40 Gy in 16 frac-
tions without boost RT or 39 Gy in 13 fractions with boost RT.
Table 2. Postmastectomy RT
Survey responses
Respondents 
No. (%)
Use of hypofractionation Yes 5 (7.8)
No 59 (92.1)
Fractionation schedules* 2.67 Gy×15 fractions 1 (20.0)
2.7 Gy×16 fractions 2 (40.0)
2.7 Gy×17 fractions 2 (40.0)
Use of boost RT Yes, always 8 (12.5)
Yes, selectively 16 (25.0) 
No 40 (62.5)
Use of boost RT after  
reconstruction
Yes, always 1 (1.6) 
Yes, close resection margin 25 (39.1) 
No 28 (43.8) 
Not experienced 8 (12.5) 
Others 2 (3.1) 
Use of bolus Yes, entire chest wall 24 (37.5) 
Yes, scar only 16 (25.0) 
No 12 (18.8) 
Others 12 (18.8) 
Use of bolus after  
reconstruction
Yes 7 (10.9) 
No 46 (71.9) 
Not experienced 9 (14.1) 
Others 2 (3.1) 
Employed techniques 
(duplicated)
Tangents 53 (82.8)
Intensity-modulated RT 10 (15.6)
Reverse hockey stick 4 (6.3)
Mixed photon and electron 3 (4.7)
RT=radiotherapy.
*Percentage of respondents who responded “Yes” to use of hypofractionation 
(%).
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four respondents (6.3%) always treated IMN, and 30 (46.9%) 
treated IMN only if IMN involvement was identified through 
imaging. Nine (14.1%) treated IMN for all patients with 4 or 
more axillary LNs involvement, but 25 (39.1%) additionally 
considered tumor location for decision making. Most of the 
respondents covered up to the third or fourth intercostal 
space for IMN irradiation. The most preferred RT technique 
for RNI was intensity-modulated RT for both WBRT (67.2%) 
and PMRT (54.7%).
Regarding posterior axillary boost (PAB) RT, 26 respon-
dents (40.6%) did not apply PAB at all. Eleven (17.2%) applied 
PAB for all cases, and 24 (37.5%) considered PAB in cases of 
insufficient dose delivery to axilla (Table 3).
Radiotherapy for ductal carcinoma in situ 
The majority (87.5%) of radiation oncologists did not con-
sider hypofractionated RT for DCIS treatment. The most 
common fractionation schedule was 50.4 Gy in 28 fractions 
(45.3%). Ten respondents (15.6%) had never used boost RT 
for the tumor bed, but 25 (39.1%) always used boost RT. 
About half of the respondents (45.3%) considered boost RT 
depending on clinical and pathological risk factors, including 
close resection margin (n= 28), young age (n= 9), and large 
tumor (n= 3).
Thirty-one radiation oncologists (48.4%) considered omis-
Table 3. Regional nodal irradiation
Survey responses
Respondents 
No. (%)
Indication ≥pN2 7 (10.9)
≥pN1 17 (26.6)
≥pN1 with pathologic risk factors 40 (62.5)
Pathologic risk factors 
(duplicated)
Lymph node-related parameters 39 (60.9) 
Lympho-vascular space invasion 31 (48.4) 
Molecular subtype 24 (37.5) 
Tumor size 19 (29.7)
Others 5 (7.8) 
In case of BCS with 
positive sentinel LN 
without ALND 
Standard tangents 8 (12.5)
High tangents 28 (43.8) 
High tangent or SCN 4 (6.3) 
Tangents+SCN 18 (28.1) 
Tangents+SCN+IMN 2 (3.1)
Others 4 (6.3)
IMN irradiation  
(duplicated)
Always, on RNI 4 (6.3)
≥pN2 9 (14.1) 
Involved IMN on imaging 30 (46.9) 
≥pN2 with inner tumor location 19 (29.7)
≥pN2 with central tumor location 6 (9.4) 
≥pN1 with inner tumor location 13 (20.3) 
≥pN1 with central tumor location 7 (10.9)
Others 2 (3.1)
IMN coverage Involved IMN on imaging 8 (12.5) 
Up to third intercostal space 24 (37.5) 
Up to fourth intercostal space 28 (43.8) 
Depending on tumor location 4 (6.3)
Employed techniques, 
WBRT (duplicated)
Intensity-modulated RT 43 (67.2)
Partial wide tangents 27 (42.2)
Mixed photon and electron 9 (14.1)
Employed techniques, 
PMRT (duplicated)
Intensity-modulated RT 35 (54.7)
Partial wide tangents 24 (37.5)
Mixed photon and electron 13 (20.3)
Reverse hockey stick 5 (7.8)
Posterior axillary boost 
RT
No 26 (40.6)
Yes, always 11 (17.2)
Yes, insufficient dose to axilla 24 (37.5)
Enlarged lymph node on imaging 3 (4.7)
BCS=breast-conserving surgery; LN= lymph node; ALND=axillary lymph 
node dissection; SCN=supraclavicular lymph node; IMN= internal mammary 
lymph node; RNI= regional nodal irradiation; WBRT=whole breast radiother-
apy; RT=radiotherapy; PMRT=postmastectomy radiotherapy.
Table 4. RT for ductal carcinoma in situ
Survey responses
Respondents 
No. (%)
Use of hypofractionation Yes 8 (12.5)
No 56 (87.5)
Fractionation schedules, 
WBRT
1.8 Gy×25 fractions 2 (3.1)
1.8 Gy×28 fractions 29 (45.3)*
2 Gy×25 fractions 27 (2.2)†
2.65 Gy×16 fractions 1 (1.6)
2.67 Gy×15 fractions 2 (3.1)
2.67 Gy×16 fractions 1 (1.6)*
2.7 Gy×16 fractions 3 (4.7)†
2.7 Gy×17 fractions 1 (1.6)
Boost RT Yes, always 25 (39.1) 
Yes, selectively 29 (45.3)
No 10 (15.6) 
Percentage of respondents who 
responded “Yes, selectively”
Selection criteria for boost 
RT (duplicated)
Close resection margin 28 (96.6)
Young age 9 (31.0)
Large tumor 3 (10.3)
Others 2 (6.9)
Omission of WBRT Considered 31 (48.4)
Not considered 33 (51.6)
Percentage of respondents who 
responded “Considered”
Selection criteria for  
omission of WBRT  
(duplicated)
Age 19 (61.3)
Tumor size 17 (54.8)
Patient’s preference 15 (48.4)
Status of estrogen receptor 14 (45.2)
Comorbidity 14 (45.2)
Resection margin 13 (41.9)
Nuclear grade 13 (41.9)
Van Nuys Prognostic Index 1 (3.2)
RT=radiotherapy; WBRT=whole breast radiotherapy.
*,†Two respondents used two kinds of fractionation schedules. 
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sion of WBRT after BCS for DCIS. They identified low-risk 
patients based on risk factors such as age, tumor size, patient’s 
preference, status of estrogen receptor, comorbidities, resec-
tion margin, and nuclear grade. Only one respondent consid-
ered Van Nuys Prognostic Index (Table 4).
Radiotherapy toxicity
The Radiation Therapy Oncology Group (RTOG) criteria 
was used to evaluate radiation dermatitis (RD) [12]. For RD 
prophylaxis, the most commonly used topical agent was 
EasyDew®/Easyef® (Daewoong Pharmaceutical, Seoul, Korea), 
which contains a small amount of epidermal growth factor 
(n= 25), followed by gentle soap (n= 20), and topical cortico-
steroids (n= 10). Seven respondents did not recommend RD 
prophylaxis during RT. Regarding RD treatment, the pre-
ferred treatment differed according to the severity of RD. 
Respondents used Silvadene® cream (Pfizer Inc., New York, 
USA)/dressing and antibiotics more frequently for grades 2–3 
RD with moist desquamation than grade 1 RD with dry des-
quamation. Three respondents stated that they referred pa-
tients to a dermatologist for the management of grades 2–3 
RD.
To reduce cardiotoxicity, 52 (81.2%) surveyed radiation on-
cologists employed heart-sparing techniques: intensity-mod-
ulated RT (n= 33), heart block (n= 31), deep inspiration breath 
hold technique (n= 9), and prone position (n= 6).
DISCUSSION
This is the first nationwide survey for breast RT designed by 
the Division for Breast Cancer of the KROG and endorsed by 
the KROG, although a number of similar questionnaire-based 
surveys have been conducted worldwide.
Delaney et al. [13] pointed out variations in practice would 
probably always exist and there were many reasons; prior edu-
cation and training of the radiation oncologist, institutional 
history, treatment biases of individuals, different philosophies 
on the way that cancer recurs and spreads, different interpre-
tations of the literature and different resources available. As 
expected with these reasons, our study revealed marked varia-
tions in current practices of breast RT in Korea.
For hypofractionated WBRT for DCIS and PMRT, high-
quality data are still scarce. Retrospective studies by Ciervide 
et al. [14] and Lalani et al. [15] reported similar local recur-
rences in DCIS patients whether treated with hypofraction-
ation or conventional regimen after BCS. A prospective trial 
by Koukourakis et al. [16] reported encouraging local control 
rates in high-risk subgroups and tolerable toxicity with hypo-
fractionated PMRT with amifostine cytoprotection. Another 
prospective trial by Ali and Abd AlMageed [17] reported 
equivalent disease control and cosmesis between conventional 
PMRT (50 Gy in 25 fractions) and hypofractionated PMRT 
(42 Gy in 16 fractions). This lack of high-level evidence could 
partially explain the very low use of hypofractionation in RT 
for DCIS and PMRT.
For hypofractionated WBRT for early-stage breast cancer, 
on the other hand, two trials provided high-quality evidence; 
the UK Standardisation of Breast Radiotherapy (START) Trial 
B compared 50 Gy in 25 fractions to 40 Gy in 15 fractions 
[18], while a Canadian study compared 50 Gy in 25 fractions 
to 42.5 Gy in 16 fractions [19]. No signiﬁcant difference in tu-
mor control and breast cosmesis was reported. Despite the 
high-quality evidence, one-third (35.9%) of the surveyed ra-
diation oncologists in Korea adopted hypofractionation due 
to the reasons described in the Results.
Hypofractionated RT has several advantages over conven-
tionally fractionated RT: shorter treatment period, increased 
patient convenience, and lower costs (both direct health care 
expenditures and opportunity costs to the patient and society 
due to time away from home and work) [20,21]. However, 
easily accessible medical facilities and low medical costs for 
cancer patients because of National Health Insurance along 
with widespread private insurance in Korea attenuates the ne-
cessity of hypofractionated RT. It is noteworthy that one-third 
(34.4%) of the surveyed radiation oncologists still consider the 
long-term data of hypofractionated RT insufficient despite ev-
idence-based guidelines [21,22].
Regarding RNI, there is a consensus that it should be given 
to patients with 4 or more axillary LNs involvement (pN2). 
However, there remains controversy in how patients with 1–3 
axillary LNs involvement (pN1) or patients with high-risk 
node-negative disease should be treated.
Our study demonstrated significant variability in practice 
patterns regarding not only the indication for RNI but also the 
extent of RNI. Two-thirds (62.5%) of the surveyed radiation 
oncologists considered RNI in pN1 and pathologic risk fac-
tors. It is possible that results of the National Cancer Institute 
of Canada (NCIC) MA.20 trial and the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) meta-analysis influ-
enced the current practice of RNI. Both the NCIC MA.20 trial 
and EBCTCG meta-analysis concluded that the addition of 
RNI could reduce recurrences and mortality for patients 
treated with BCS and mastectomy, respectively.
The MA.20 trial randomized patients with pN1 or high-risk 
pN0 after BCS and adjuvant systemic therapy to undergo ei-
ther WBRT or WBRT plus RNI (including SCN, IMN, and 
axilla), and patients were stratiﬁed according to the number of 
axillary LNs removed and involved. The MA.20 trial conclud-
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ed that the addition of RNI reduced breast cancer recurrences 
but did not improve overall survival [23]. The EBCTCG meta-
analysis analyzed 8,135 patients from 22 trials that randomly 
assigned patients to treatment groups of either no PMRT or 
PMRT (including SCN, IMN, and axilla), and showed PMRT 
reduced both recurrence and breast cancer mortality in pN1 
as well as pN2 [24]. However, these two studies with high-lev-
el evidence did not influence current Korean practitioners re-
garding the extent of RNI. Approximately half (46.9%) of the 
respondents treated IMN only if involved IMN was identified 
on imaging, and only four (6.3%) routinely treated IMN when 
RNI was applied.
In the setting of ACOSOG Z0011 [25], which is of an early-
stage breast cancer patient with 1–2 positive sentinel LNs un-
dergoing BCS without further axillary dissection, 12.5% and 
50.0% of the respondents used standard and high tangents, 
respectively. These results were consistent with those of an 
Australian study; 20.4% and 48.9% of practitioners used stan-
dard and high tangents, respectively.
Although the literature has demonstrated that RT halves ip-
silateral breast tumor recurrence after BCS for DCIS, patients 
show a favorable survival outcome with a 10-year survival rate 
> 98%, regardless of the intensity of locoregional therapy 
[26,27]. Given the favorable prognosis of DCIS, efforts to 
identify patients who are suitable for less-intensive treatment 
have been made [28,29].
In a recent survey from the United States (using the Georgia 
and Los Angeles County Surveillance, Epidemiology, and End 
Results registries), one quarter of the patients omitted RT after 
BCS in DCIS, and the most common reason for omitting RT 
was due to advice from a clinician. A total of 74% of radiation 
oncologists would discuss RT omission as an option, but 70% 
would still recommend WBRT in a clinical scenario of a 
healthy, 65-year-old woman with favorable prognosis DCIS 
who had undergone BCS [30]. In our study, 48.4% of radia-
tion oncologists considered omission of WBRT after BCS for 
DCIS in low-risk patients based on clinical and pathologic 
factors. However, because our questionnaire did not give a 
specific scenario, it was difficult to compare the results be-
tween the two studies.
A number of trials have evaluated the omission of RT after 
BCS for patients with favorable factors in DCIS. The Eastern 
Cooperative Oncology Group selected patients with low-risk 
clinical and pathologic characteristics and observed them 
without WBRT; the number of invasive ipsilateral breast 
events increased through 12 years of follow-up, without pla-
teau [28]. The RTOG 9804 trial selected patients with low-risk 
DCIS and randomized them to either observation or WBRT. 
The results were promising, contrary to those of the former 
study, with a 6.7% local failure occurrence at 7 years without 
WBRT. However, even within this low-risk group, the addi-
tion of WBRT reduced the risk of local failure to 0.8%, and 
longer follow-up data is needed [29].
The aim of the present study was to provide baseline infor-
mation to physicians about patterns of practice for breast RT 
in Korea. The results showed a high-degree of variation on is-
sues of breast RT, such as hypofractionation, RNI, and RT 
omission in DCIS. These issues are also covered by the most 
recent Korean Clinical Practice Guideline for Breast Cancer, 
but definite conclusions cannot be reached because additional 
evidence is needed.
Although the findings of this study are valuable, some as-
pects of this study require further consideration. A question-
naire-based survey is a very useful method of study to reveal 
practice variations or controversy on treatments in the medi-
cal field. However, the results of the survey are based on self-
reported data from respondents and might not reflect actual 
physicians’ practices. Moreover, we could assume that there is 
a wide range in the number of patients treated by each sur-
veyed radiation oncologists. In other words, the response that 
50% of the respondents consider hypofractionation does not 
mean that 50% of patients are treated with hypofractionation. 
Population-based studies utilizing data from cancer registries 
or data on insurance claims are needed to figure out the actual 
state of practice.
CONCLUSION
This is the first nationwide survey that represents the cur-
rent practice of RT for breast cancer in Korea. The results of 
this survey showed wide variations in the patterns of practice 
in breast RT. Standard guidelines are needed, especially for 
RNI and omission of RT for DCIS.
CONFLICT OF INTEREST
The authors declare that they have no competing interests.
ORCID
Hae Jin Park https://orcid.org/0000-0003-3891-8952
Kyung Hwan Shin https://orcid.org/0000-0002-5852-7644
REFERENCES
1. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based 
Regional Cancer Registries. Cancer statistics in Korea: incidence, mor-
tality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-
250  Hae Jin Park, et al.
http://ejbc.kr https://doi.org/10.4048/jbc.2018.21.e37
16. 
2. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast 
cancer significantly improves overall survival: the missing link. Radiother 
Oncol 2000;55:263-72. 
3. Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, 
et al. Radiotherapy after breast-preserving surgery in women with 
localized cancer of the breast. N Engl J Med 1993;328:1587-91. 
4. Ceilley E, Jagsi R, Goldberg S, Grignon L, Kachnic L, Powell S, et al. 
Radiotherapy for invasive breast cancer in North America and Europe: 
results of a survey. Int J Radiat Oncol Biol Phys 2005;61:365-73. 
5. Nguyen K, Mackenzie P, Allen A, Dreosti M, Morgia M, Zissiadis Y, et 
al. Breast interest group faculty of radiation oncology: Australian and 
New Zealand patterns of practice survey on breast radiotherapy. J Med 
Imaging Radiat Oncol 2017;61:508-16. 
6. Delaney GP, Gandhidasan S, Walton R, Terlich F, Baker D, Currow D. 
The pattern of use of hypofractionated radiation therapy for early-stage 
breast cancer in New South Wales, Australia, 2008 to 2012. Int J Radiat 
Oncol Biol Phys 2016;96:266-72. 
7. Algara M, Arenas M, De Las Peñas Eloisa Bayo D, Muñoz J, Carceller 
JA, Salinas J, et al. Radiation techniques used in patients with breast 
cancer: results of a survey in Spain. Rep Pract Oncol Radiother 2012; 
17:122-8. 
8. van der Laan HP, Hurkmans CW, Kuten A, Westenberg HA; EORTC-
ROG Breast Working Party. Current technological clinical practice in 
breast radiotherapy: results of a survey in EORTC-Radiation Oncology 
Group affiliated institutions. Radiother Oncol 2010;94:280-5. 
9. Hui Z, Li Y, Yu Z, Liao Z. Survey on use of postmastectomy radiotherapy 
for breast cancer in China. Int J Radiat Oncol Biol Phys 2006;66:1135-
42. 
10.  Keum KC, Shim SJ, Lee IJ, Park W, Lee SW, Shin HS, et al. The 1998, 
1999 patterns of care study for breast irradiation after mastectomy in 
Korea. J Korean Soc Ther Radiol Oncol 2007;25:7-15.
11. Kang JK, Kim MS, Jang WI, Seo YS, Kim HJ, Cho CK, et al. The clinical 
utilization of radiation therapy in Korea between 2009 and 2013. Radiat 
Oncol J 2016;34:88-95. 
12. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European Organization for Re-
search and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 
1995;31:1341-6. 
13. Delaney G, Blakey D, Drummond R, Kenny L, Centre RO. Breast 
radiotherapy: an Australasian survey of current treatment techniques. 
Australas Radiol 2001;45:170-8. 
14. Ciervide R, Dhage S, Guth A, Shapiro RL, Axelrod DM, Roses DF, et al. 
Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) 
after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 
2012;83:e159-64. 
15. Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, 
Hanna W, et al. Long-term outcomes of hypofractionation versus 
conventional radiation therapy after breast-conserving surgery for 
ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 
2014;90:1017-24. 
16. Koukourakis MI, Panteliadou M, Abatzoglou IM, Sismanidou K, Sivridis 
E, Giatromanolaki A. Postmastectomy hypofractionated and accelerat-
ed radiation therapy with (and without) subcutaneous amifostine cyto-
protection. Int J Radiat Oncol Biol Phys 2013;85:e7-13. 
17. Ali EM, Abd AlMageed MK. Post-mastectomy hypofractionation 
radiotherapy in breast cancer patients. Cancer Oncol Res 2014;2:87-93.
18. START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett 
JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiothera-
py (START) Trial B of radiotherapy hypofractionation for treatment of 
early breast cancer: a randomised trial. Lancet 2008;371:1098-107. 
19. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. 
Randomized trial of breast irradiation schedules after lumpectomy for 
women with lymph node-negative breast cancer. J Natl Cancer Inst 
2002;94:1143-50.
20. Suh WW, Pierce LJ, Vicini FA, Hayman JA. A cost comparison analysis 
of partial versus whole-breast irradiation after breast-conserving sur-
gery for early-stage breast cancer. Int J Radiat Oncol Biol Phys 
2005;62:790-6. 
21. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott 
GS, et al. Fractionation for whole breast irradiation: an American Soci-
ety for Radiation Oncology (ASTRO) evidence-based guideline. Int J 
Radiat Oncol Biol Phys 2011;81:59-68. 
22. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. 
Radiation therapy for the whole breast: executive summary of an 
American Society for Radiation Oncology (ASTRO) evidence-based 
guideline. Pract Radiat Oncol 2018;8:145-52. 
23. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, 
et al. Regional nodal irradiation in early-stage breast cancer. N Engl J 
Med 2015;373:307-16. 
24. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale 
P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy 
after mastectomy and axillary surgery on 10-year recurrence and 20-
year breast cancer mortality: meta-analysis of individual patient data for 
8135 women in 22 randomised trials. Lancet 2014;383:2127-35. 
25. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, 
Blumencranz PW, et al. Axillary dissection vs no axillary dissection in 
women with invasive breast cancer and sentinel node metastasis: a ran-
domized clinical trial. JAMA 2011;305:569-75. 
26. Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, et 
al. Trends in treatment patterns and outcomes for ductal carcinoma in 
situ. J Natl Cancer Inst 2015;107:djv263. 
27. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality 
after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015;1:888-
96. 
28. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, et al. 
Surgical excision without radiation for ductal carcinoma in situ of the 
breast: 12-year results from the ECOG-ACRIN E5194 Study. J Clin 
Oncol 2015;33:3938-44. 
29. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, 
et al. RTOG 9804: a prospective randomized trial for good-risk ductal 
carcinoma in situ comparing radiotherapy with observation. J Clin 
Oncol 2015;33:709-15. 
30. Shumway DA, McLeod CM, Morrow M, Li Y, Kurian AW, Sabolch A, 
et al. Patient experiences and clinician views on the role of radiation 
therapy for ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 
2018;100:1237-45.
